Literature DB >> 15642408

Electron transfer in N-hydroxyurea complexes with iron(III).

Biljana Nigović1, Nikola Kujundzić, Kresimir Sanković.   

Abstract

Redox behaviour of the iron(III) complex with the antitumour drug hydroxyurea was studied by cyclic voltammetry. The complex underwent a one-electron reduction, followed by an irreversible chemical reaction (EC mechanism) in which a ligand was released. In addition, it was found that the hydroxyurea gave up an electron to iron(III) in solution. Differential-pulse voltammetry revealed an increase in the concentration of the generated iron(II) species. Electron paramagnetic resonance (EPR) spectroscopy studies of the oxidative degradation of hydroxyurea confirmed formation of the radical species H2N-CO-NHO*. Electrochemical data for iron(III) complexes of hydroxyurea and its structural analogue 3-ethylhydroxyurea, which also exhibits antitumour activity, show the same mechanism involved in the electron transfer. The observed redox properties indicate that hydroxyurea may interfere with electron transfer processes in biological systems after binding to iron-containing ribonucleotide reductase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15642408     DOI: 10.1016/j.ejmech.2004.09.012

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  5 in total

1.  Replication Rapidly Recovers and Continues in the Presence of Hydroxyurea in Escherichia coli.

Authors:  Samvel A Nazaretyan; Neda Savic; Michael Sadek; Brandy J Hackert; Justin Courcelle; Charmain T Courcelle
Journal:  J Bacteriol       Date:  2018-02-23       Impact factor: 3.490

Review 2.  Nucleotide metabolism, oncogene-induced senescence and cancer.

Authors:  Katherine M Aird; Rugang Zhang
Journal:  Cancer Lett       Date:  2014-01-29       Impact factor: 8.679

Review 3.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

4.  Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.

Authors:  Rebecca B Klisovic; William Blum; Xiaohui Wei; Shujun Liu; Zhongfa Liu; Zhiliang Xie; Tamara Vukosavljevic; Cheryl Kefauver; Lenguyen Huynh; Jiuxia Pang; James A Zwiebel; Steven Devine; John C Byrd; Michael R Grever; Kenneth Chan; Guido Marcucci
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

5.  DNA replication inhibitor hydroxyurea alters Fe-S centers by producing reactive oxygen species in vivo.

Authors:  Meng-Er Huang; Céline Facca; Zakaria Fatmi; Dorothée Baïlle; Safia Bénakli; Laurence Vernis
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.